Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports

INTRODUCTION: Lenvatinib (LEN) is a novel potent multi-tyrosine kinase inhibitor, approved as first-line treatment for unresectable hepatocellular carcinoma (HCC). Considering its high objective response rate, LEN therapy could be expected to achieve downstaging of tumors and lead to conversion ther...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Medicine (Baltimore)
Main Authors: Tomonari, Tetsu, Sato, Yasushi, Tanaka, Hironori, Tanaka, Takahiro, Taniguchi, Tatsuya, Sogabe, Masahiro, Okamoto, Koichi, Miyamoto, Hiroshi, Muguruma, Naoki, Saito, Yu, Imura, Satoru, Bando, Yoshimi, Shimada, Mitsuo, Takayama, Tetsuji
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2020
Assuntos:
5700
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7571946/
https://ncbi.nlm.nih.gov/pubmed/33080748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000022782
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados